Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

Trial Identifier: D2560C00013
Sponsor: MedImmune, LLC
Collaborator:
AstraZeneca
NCTID:: NCT03143101
Start Date: May 2017
Primary Completion Date: September 2017
Study Completion Date: September 2017
Condition: Healthy Volunteers; Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Spanish Translation

Trial Locations

Country Location
United States of America, GA Savannah, GA, United States of America, 31405
United States of America, KY Bardstown, KY, United States of America, 40004
United States of America, MO St. Louis, MO, United States of America, 63141
United States of America, NE Norfolk, NE, United States of America, 68701
United States of America, NE Omaha, NE, United States of America, 68134
United States of America, NY Binghamton, NY, United States of America, 13901
United States of America, SD Dakota Dunes, SD, United States of America, 57049
United States of America, TX Ft. Worth, TX, United States of America, 76104
United States of America, TX San Angelo, TX, United States of America, 76904
United States of America, TX Tomball, TX, United States of America, 77375
United States of America, UT Salt Lake City, UT, United States of America, 84124
United States of America, UT West Jordan, UT, United States of America, 84088